Lampalizumab
| Monoclonal antibody | |
|---|---|
| Type | Fab fragment |
| Source | Humanized (from mouse) |
| Target | CFD |
| Clinical data | |
| Routes of administration | Intravitreal |
| ATC code | none |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | 1278466-20-8 |
| IUPHAR/BPS | 8294 |
| ChemSpider | none |
| Chemical and physical data | |
| Formula | C2068H3214N546O676S13 |
| Molar mass | 46.96 kg/mol |
Lampalizumab (INN) is an antigen-binding fragment of a humanized monoclonal antibody designed for the treatment of geographic atrophy (atrophy of the retinal pigment epithelium) secondary to age-related macular degeneration. It binds to complement factor D (CFD).[1][2]
Enrollment in Phase 3 clinical trials was initiated in 2014.[3] Phase 3 trials are usually conducted in order to establish the effectiveness of a drug, and compare the results to known alternative treatments.[4]
References
- ↑ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Lampalizumab, American Medical Association.
- ↑ Roche starts Phase III trials of lampalizumab, PharmaTimes
- ↑ What are clinical trial phases?, NIH - US National Library of Medicine.
This article is issued from Wikipedia - version of the 12/1/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.